(Q46753360)

24 December 2017

title

Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy (English)

1 reference

24 December 2017

0 references

1 reference

5

Kwaku Ohene-Frempong

1 reference

24 December 2017

Efemwonkiekie W Iyamu

1

1 reference

24 December 2017

Renee Cecil

2

1 reference

24 December 2017

Leslie Parkin

3

1 reference

24 December 2017

Gerald Woods

4

1 reference

24 December 2017

Toshio Asakura

6

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

24 December 2017

British Journal of Haematology

published in

1 reference

24 December 2017

volume

131

1 reference

24 December 2017

issue

3

1 reference

24 December 2017

page(s)

389-394

1 reference

24 December 2017

Purification and properties of arginase from human liver and erythrocytes

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05772.X

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05772.X

Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05772.X

Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05772.X

Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05772.X

Combined use of nonmyelosuppressive nitrosourea analogues with hydroxyurea in the induction of F-cell production in a human erythroleukemic cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05772.X

Nitric oxide production from hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05772.X

Nitric oxide in skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05772.X

Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05772.X

Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05772.X

Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05772.X

n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05772.X

Evidence for a metabolic shift of arginine metabolism in sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05772.X

10.1111/J.1365-2141.2005.05772.X

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

PubMed ID

16225659

1 reference

24 December 2017